FDA to expand public education campaign to focus on prevention of youth e-cigarette use
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration announced it would pursue a strategic, new public health education campaign aimed at discouraging the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) by kids. The agency plans to expand its "The Real Cost" public education campaign to include messaging to teens about the dangers of using these products this fall while developing a full-scale campaign to launch in 2018.
FDA approves treatment for chronic graft versus host disease
- Details
- Category: FDA
The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy for the treatment of cGVHD.
FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death
- Details
- Category: FDA
The U.S. Food and Drug Administration today announced a new comprehensive plan for tobacco and nicotine regulation that will serve as a multi-year roadmap to better protect kids and significantly reduce tobacco-related disease and death. The approach places nicotine, and the issue of addiction, at the center of the agency's tobacco regulation efforts.
FDA approves Vosevi for Hepatitis C
- Details
- Category: FDA
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs - sofosbuvir and velpatasvir - and a new drug, voxilaprevir.
FDA tackles drug competition to improve patient access
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of generic drug applications where competition is limited.
Statement from FDA Commissioner Scott Gottlieb, M.D., on the importance of the Drug Quality and Security Act and overseeing the safety of compounded drugs
- Details
- Category: FDA
In late 2012, the United States faced the most serious outbreak associated with contaminated compounded drugs in recent history, involving hundreds of people, in many states, who developed fungal infections related to a compounded product. It was an incident that resulted in dozens of deaths.
FDA approves first generic Strattera for the treatment of ADHD
- Details
- Category: FDA
The U.S. Food and Drug Administration has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited gained approval to market atomoxetine in multiple strengths.
More Pharma News ...
- Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions
- FDA approves first cancer treatment for any solid tumor with a specific genetic feature
- FDA approves drug to treat ALS
- FDA approves first treatment for a form of Batten disease
- FDA takes action against 14 companies for selling illegal cancer treatments
- FDA approves first drug to treat tardive dyskinesia
- FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions